Belite Bio, Inc (BLTE)

NASDAQ: BLTE · Real-Time Price · USD

149.18

-5.86 (-3.78%)

Mar 26, 2026, 4:00 PM EDT - Market closed

Belite Bio Employees

Belite Bio had 25 employees as of December 31, 2024. The number of employees increased by 5 or 25.00% compared to the previous year.

Employees

25

Change (1Y)

5

Growth (1Y)

25.00%

Revenue / Employee

n/a

Profits / Employee

-$3,104,440

Market Cap

5.87B

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2024	25	5	25.00%
Dec 31, 2023	20	4	25.00%
Dec 31, 2022	16	4	33.33%
Dec 31, 2021	12	-	-

Related Stocks

Company Name	Employees
Caris Life Sciences	1,846
PTC Therapeutics	991
Rhythm Pharmaceuticals	414
Mirum Pharmaceuticals	372
Xenon Pharmaceuticals	370
Apogee Therapeutics	261
Cogent Biosciences	258
Kymera Therapeutics	238

Employee Rankings

BLTE News

23 days ago - Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript - Seeking Alpha
24 days ago - Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
4 months ago - Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
4 months ago - Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares - GlobeNewsWire
4 months ago - Belite Bio, Inc (BLTE) Discusses Positive Topline Results from Phase III DRAGON Trial of Tinlarebant in Stargardt Disease Transcript - Seeking Alpha
4 months ago - Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease - Benzinga
4 months ago - Belite Bio's drug for genetic eye disease meets main goal in late-stage trial - Reuters
4 months ago - New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease - GlobeNewsWire